Ariana continues global expansion from US to Japan with KEM(R) data analytics software and services technology.
Ariana Pharma, the premium provider of advanced, non-statistical clinical data and biomarker analytics technology across life science industries as well as the FDA, today announces the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS), the Japanese supplier of services for R&D solutions.
CTCLS will distribute Ariana’s KEM(R) data analytics software and services technology to Japanese markets. Ariana selected CTCLS as its Japanese distribution partner because of the company’s dominant presence in Japan. CTCLS is a leading R&D service provider, offering total solutions to major industries and specializing in the pharmaceutical sector.
Ariana’s KEM(R), or Knowledge Extraction and Management, is a novel, association rules-based (non-statistical) data-analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect. In the life science industry, KEM saves sponsors both time and money by optimizing clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints.
“In the first half of 2012, we expanded west from Europe to launch our US office, and now we’re progressing into the Far East with the CTCLS distribution agreement,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma. “This deal with CTCLS will provide an excellent entry into Asia and the world’s third largest biotechnology market. We expect the ongoing growth of Japanese companies in medicine development, diagnostics and biomarker studies will further increase demand for Ariana’s KEM(R) software.”